Forbes.com // Feb 23, 2019 .
Microbiome Research Will Accelerate The Blue Biotechnology Industry .
... Microbiome research will accelerate developments in the blue biotechnology industry. Only a tiny fraction of marine microorganisms can be cultured and tested for bioactive compounds in labs, but microbiome research uses next-generation sequencing to simply capture the genetic sequences of marine organisms. This is much easier than finding the exact conditions required to grow the microorganisms in the lab.
The genetic sequences can be analyzed for putative or known function of different genes. This process generates huge amounts of data that can be mined for genes that produce natural products of interest. In its infancy, the global blue biotechnology market could reach almost $5 billion by next year, with this projection excluding the potential discoveries from microbiome research.
PharmaMar, based in Madrid, discovered and produces Yondelis, a medicine to treat soft tissue sarcomas and ovarian cancer. PharmaMar focused their efforts on discovering anticancer compounds from the ocean and discovered the active ingredient of Yondelis in a sea squirt. PharmaMar netted $203 million in 2017.
...
CAMBIO DE DISCURSO : LA SECOND-LINE SCLC-ES TRAS EL FIASCO DE LA FASE III LAGOON YA MEJOR NI NOMBRARLA...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE . JazzPharma TO WITHDRAW LURBINECTEDIN WITH US_FDA IN SECOND-LINE SCLC-ES.. SI NO EXISTIERA IMFORTE...AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN ... 2 DE OCTUBRE DE 2028 ... ES LA FECHA MÁS TEPMPRANA PARA LA POSIBLE ENTRADA DE GENÉRICOS .





